Current Issue

From Aberrant Results to Alternative Methods: Strengthening Pharmaceutical Laboratory Deci...

Dr Markus Funk, Operations Director Analytics Axel. H. Schroeder, Operations Director Micr...

Sterility Assurance – An Enabler to Comply with Annex 1

Robert Dream, Managing Director, HDR Company LLC

Harmonization of Viral Segregation Strategy for a Manufacturing Network with Multiple Faci...

Bonnie K. Shum, Senior Director, Product Technical Leader, Genentech

Raw Material Qualification – A Practical Approach

Aurora Henry, GMP Quality/ Raw Material Quality/Material Control Leader

Caustic Stability of Amsphere A3 : Cycling Study with 0.5 M NaOH

JSR Life Sciences



Headline News

Kyverna completes BLA submission for miv-cel in stiff person syndrome


CAPLYTA shows rapid improvement in bipolar mania in second pivotal Phase III study


FDA clears expanded ENT indication for Johnson & Johnson’s HARMONIC 1100 Shears


Read All Headlines

Upcoming Webinars

View All Upcoming Webinars

Past Webinars

FDA Perspective on Aseptic Process Simulation for Cell Therapy Product Manufacturing

Presented by Lily Koo, Consumer Safety Officer at Food and Drug Administration and Keen Chung, Principal Scientist (Upstream Process) at Pall Biotech, Analytics Lead
16th October 2019


Addressing Material Properties in the Design of a Direct Compression Continuous Manufacturing System

Presented by Professor Fernando Muzzio, Professor II in the Department of Chemical and Biochemical Engineering at Rutgers
16th January 2014


Commercial Cell Therapy Experience Using Mycoplasma NAT For Product Release: Five-Year Review

Presented by John Duguid, Executive Director, Research & Development at Vericel Corporation and Lori Daane, Pharma Microbiology Sr. Scientific Director at bioMérieux and Mike Brewer, Director, Global Principal Consultant, Regulatory, BioProduction at Thermo Fisher Scientific
01st November 2022


View All Past Webinars

Featured Companies

 

View All Companies

© 2026 biopharma-asia.com. All rights reserved. Privacy Policy

Biopharma Asia